Farestos is the commercial name of toremifene citrate, produced by the Moldovan manufacturer of sports pharmacology products Pharmacom Labs. Developed a whole group of similar drugs at the end of the twentieth century in Finland with completely different goals, medical. Selective estrogen receptor modulators have been widely used as the main means of post-course therapy after the use of anabolic androgenic steroids. What effect does farestos pharmacom have on the body after a course of anabolic androgenic steroids? Post-course therapy in bodybuilding and other strength sports disciplines plays an important role.Farestos (active ingredient-toremifene citrate) is a selective estrogen receptor modulator (SERM) derived from triphenylethylene. Toremifene was patented and approved in Europe in the mid-1990s for the treatment of metastatic ER+ breast cancer in postmenopausal women.
In bodybuilding, toremifene citrate is used by men as a post-cycle therapy (PCT) drug to counteract and / or block some of the effects of excess estradiol in the body obtained by aromatizing the various androgens used. Toremifene is used, in particular, to restore the level of endogenous testosterone in the blood, as well as to prevent the estrogen-related side effect of gynecomastia.
Toremifene stimulates the hypothalamus, which in turn stimulates the anterior pituitary gland to secrete gonadotropins. Gonadotropins are follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH stimulates (in men) spermatogenesis, and LH stimulates the Leydig cells of the testicles to secrete more testosterone. This feedback mechanism is known as the hypothalamic-pituitary-testicular axis (HPTA). This leads to an increase in the body's own testosterone production, which leads to an increase in testosterone levels in the blood to compensate for the decrease in exogenous steroid levels. This is vital for minimizing post-cycle muscle loss.
As for its anti-estrogenic activity, it should be noted that toremifene citrate, being a SERM, is a true estrogen blocker compared to aromatase inhibitors. Toremifene citrate blocks the activity of estradiol at its target receptor sites in various tissues, and it does this by binding more strongly to the estradiol receptors in these tissues than estradiol itself, effectively occupying the space that estradiol would normally occupy. Toremifene binds to the receptor site and remains inert (does not activate the receptors). This leads to the inability of estradiol to bind to these receptors, since they were already occupied by toremifene.
Therefore, the dosage of toremifene for a more effective increase in testosterone production should be in the range of up to 120 mg per day. This dose can be maintained for the first week of the PCT, 100 mg / day for the second week of the PCT, and then 60 mg / day for the remaining 3-4 weeks of the PCT.
|Active substance||Toremifene citrato|
|Active ingredient, mg||20|
|1 pill, mg||20|
|Blister, pills||2, 50|
|Packing||Blister (50 pills), Packing (2 blisters)|